Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028

MT Newswires Live09-03

Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggregate principal amount of 3.875% senior unsecured notes due 2028.

The biopharmaceutical company deployed about $68 million in cash toward the effort, representing an average repurchase price of 90.6% of face value.

The buyback reduces the aggregate principal amount of senior unsecured notes due 2028 to approximately $364.7 million, the company said, adding that it continues to evaluate market conditions for refinancing the remaining outstanding senior unsecured notes, which mature in Aug. 2028.

Shares of the company were up 1.9% in Thursday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664874925?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664874925","market":"sg","top_or_hot":-1,"title":"Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggregate principal amount of 3.875% senior unsecured notes due 2028.</p><p>The biopharmaceutical company deployed about $68 million in cash toward the effort, representing an average repurchase price of 90.6% of face value.</p><p>The buyback reduces the aggregate principal amount of senior unsecured notes due 2028 to approximately $364.7 million, the company said, adding that it continues to evaluate market conditions for refinancing the remaining outstanding senior unsecured notes, which mature in Aug. 2028.</p><p>Shares of the company were up 1.9% in Thursday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggregate principal amount of 3.875% senior unsecured notes due 2028.</p><p>The biopharmaceutical company deployed about $68 million in cash toward the effort, representing an average repurchase price of 90.6% of face value.</p><p>The buyback reduces the aggregate principal amount of senior unsecured notes due 2028 to approximately $364.7 million, the company said, adding that it continues to evaluate market conditions for refinancing the remaining outstanding senior unsecured notes, which mature in Aug. 2028.</p><p>Shares of the company were up 1.9% in Thursday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664874925","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664874925","pubTimestamp":1788438210,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  said Thursday that it has completed the repurchase of $75 million aggregate principal amount of 3.875% senior unsecured notes due 2028.The biopharmaceutical company deployed about $68 million in cash toward the effort, representing an average repurchase price of 90.6% of face value.The buyback reduces the aggregate principal amount of senior unsecured notes due 2028 to approximately $364.7 million, the company said, adding that it continues to evaluate market conditions for refinancing the remaining outstanding senior unsecured notes, which mature in Aug. 2028.Shares of the company were up 1.9% in Thursday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4583":"猴痘概念","NRGO":"MicroSectors U S Big Oil Index 2X Leveraged","EBS":"Emergent Biosolutions"},"translate_title":"Emergent BioSolutions 回购 2028 年到期的 7500 万美元优先无担保票据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRGO":0.67,"EBS":1.5},"content_text":"Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggregate principal amount of 3.875% senior unsecured notes due 2028.The biopharmaceutical company deployed about $68 million in cash toward the effort, representing an average repurchase price of 90.6% of face value.The buyback reduces the aggregate principal amount of senior unsecured notes due 2028 to approximately $364.7 million, the company said, adding that it continues to evaluate market conditions for refinancing the remaining outstanding senior unsecured notes, which mature in Aug. 2028.Shares of the company were up 1.9% in Thursday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664874925","isCrawlerRequest":true}